

February 16, 2024 | Issue 309

Editor's note

This note is produced every Friday by <u>KPMG</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

> Subscribe here



CMS released a <u>proposed rule</u> strengthening oversight of Medicare accrediting organizations in response to <u>conflict of interest and</u> <u>performance concerns</u> identified by the agency.

CMS announced <u>changes to its data dissemination policy</u>, eliminating physical access to certain CMS data, citing increased data breaches and data security risks; <u>researchers expressed concerns</u> regarding the impact on access to CMS data.

CMS issued <u>additional guidance</u> on the Inflation Reduction Act's (IRA) Medicare Prescription Payment Plan, including outreach and education requirements, pharmacy processes, and operational considerations; the payment plan allows Medicare beneficiaries to spread prescription drug costs across monthly payments.

FTC/HHS issued a <u>RFI</u> on pharmaceutical group purchasing organizations' (GPOs) and drug wholesalers' compliance with antitrust laws and potential role in generic drug shortages.

HHS/HUD <u>announced</u> eight states and D.C. were selected for participation in the <u>Housing and Services Partnership Accelerator (Accelerator)</u>; the inter-agency initiative aims to reduce homelessness by addressing healthrelated social needs... HHS <u>announced</u> six states were selected for participation in the Postpartum Maternal Health Collaborative, which funds initiatives to improve equity in post-partum care.

0

Healthcare law and policy news

Gilead Sciences Inc. to <u>acquire</u> CymaBay Therapeautics Inc., an experimental liver disease drug developer (\$4.3B).

A federal judge dismissed a <u>PhRMA-backed lawsuit</u> opposing Medicare's new <u>drug price negotiation program</u>; the suit is <u>one of eight pharmaceutical</u> <u>industry and trade-group backed challenges</u> to the negotiations.

<u>A 2024 Chartis report</u> found 50% of rural hospitals are operating at a loss, up 7% from 2023; increasing MA penetration and disruption of traditional reimbursement mechanisms for rural hospitals cited as potential drivers... <u>A new Private Equity Stakeholder Project report</u> found private equity investment in MA declined to just four deals in 2023 after a record high of 19 in 2021; the report cited a stricter regulatory climate and high interest rates as potential contributing factors.

A National Association of ACOs (NAACOs) investigation <u>alleges a group of</u> <u>high-volume catheter suppliers may have fraudulently billed Medicare</u> for nearly \$2B from 2022-2023.

Baptist Health <u>filed a suit</u> against Humana alleging underpayments for outpatient drugs purchased via the 340B discount program; the suit argues Humana should retroactively adjust its MA reimbursement rates to align with a 2022 Supreme Court decision that undid 340B rate cuts.

0

Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. USCS011380-1B

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.